FDA Approval of Desmopressin for Nocturia

JAMA. 2017 May 23;317(20):2059-2060. doi: 10.1001/jama.2017.4316.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adult
  • Advisory Committees
  • Child
  • Deamino Arginine Vasopressin / adverse effects
  • Deamino Arginine Vasopressin / therapeutic use*
  • Drug Approval*
  • Humans
  • Hyponatremia / chemically induced
  • Nocturia / drug therapy*
  • Nocturia / etiology
  • Product Surveillance, Postmarketing
  • United States
  • United States Food and Drug Administration

Substances

  • Deamino Arginine Vasopressin